newsfilter
← Latest News
Business Wire·

PepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

PEPG
  • PepGen reported positive Phase 2 FREEDOM2-DM1 results for the 10 mg/kg cohort, achieving a 46.5% mean splicing correction & improvements in functional measures like hand grip strength & mobility.
  • The 12.5 mg/kg FREEDOM2-DM1 cohort is fully enrolled with participants receiving up to three doses; results are expected in the first half of 2027.
  • Interim safety data for the 10 mg/kg FREEDOM-OLE cohort & clinical data for the 5 mg/kg cohort are expected in January 2027.
  • PepGen holds $104.8 million in cash as of September 30, 2026, which is sufficient to fund operations into 2028.
  • The company reported a net loss of $19.4 million for the quarter ended September 30, 2026, with research & development expenses at $14.5 million & general & administrative expenses at $5.9 million.
  • An independent Data and Safety Monitoring Board recommended advancing the FREEDOM2 trial to the 12.5 mg/kg dose & approved dose escalation in the FREEDOM-OLE study from 5 mg/kg to 10 mg/kg.
  • PepGen plans to initiate an expansion cohort to generate longer-term data up to 9 months, running parallel to the 12.5 mg/kg cohort.
  • Data from FREEDOM2 & FREEDOM-OLE studies are expected to support an end-of-Phase 2 meeting in the second half of 2027, pending resolution of a partial clinical hold issued by the FDA in March 2026.
  • The FDA selected PGN-EDODM1 for its CMC Development and Readiness Pilot program in October 2026 to accelerate manufacturing development strategies.